Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Licaminlimab · ESBA-1622, LME-636

Other · developed by Oculis

Phase 2/3 Most advanced trial
OCS Developer
1 Registered trials

What is Licaminlimab?

Licaminlimab is an investigational eye drop given three times daily for 29 days in a trial in dry eye disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ESBA-1622, LME-636
Drug type
Other
Therapy area
Ophthalmology
Developer
Oculis (OCS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
D5ZJ707VIR

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07548632 Phase 2/3 Dry Eye Disease (DED) Active not recruiting OCS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye Disease (DED)

More from Oculis

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OCS page.

Follow OCS, the company behind Licaminlimab

See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.